[1st experiences in the treatment of ovarian tumors with Peptichemio].
D000230:Adenocarcinoma / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D004341:Drug Evaluation; D004407:Dysgerminoma / Q000188:drug therapy; D005260:Female; D006106:Granulosa Cell Tumor / Q000188:drug therapy; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D018310:Sertoli-Leydig Cell Tumor / Q000188:drug therapy; D014717:Vertigo / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D010455:Peptides
Prime esperienze nel trattamento dei tumori ovarici con Peptichemio